Disease Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown Sunitinib colon cancer not applicable detail...
Unknown unknown Sorafenib + Fluorouracil colon cancer not applicable detail...
Unknown unknown Valproic Acid + Mitomycin C colon cancer not applicable detail...
Unknown unknown Vorinostat colon cancer not applicable detail...
Unknown unknown Panobinostat colon cancer not applicable detail...
Unknown unknown Lenvatinib colon cancer not applicable detail...
KRAS G13D Buparlisib colon cancer no benefit detail...
APC inact mut Sirolimus colon cancer sensitive detail...
APC inact mut Vinorelbine colon cancer sensitive detail...
APC inact mut Vandetanib colon cancer sensitive detail...
Unknown unknown Decitabine colon cancer not applicable detail...
TP53 wild-type MK-1775 + PF-00477736 colon cancer sensitive detail...
Unknown unknown Vandetanib colon cancer not applicable detail...
Unknown unknown Temsirolimus + Cetuximab colon cancer not applicable detail...
FBXW7 loss Sirolimus colon cancer sensitive detail...
Unknown unknown GANT61 colon cancer not applicable detail...
APC inact mut CGP049090 colon cancer sensitive detail...
APC inact mut ICG-001 colon cancer sensitive detail...
APC inact mut MF tricyclic colon cancer sensitive detail...
APC inact mut PKF115-584 colon cancer sensitive detail...
APC inact mut StAx-35 colon cancer sensitive detail...
Unknown unknown Y15 colon cancer not applicable detail...
BRAF V600E PD-0325901 colon cancer sensitive detail...
TP53 wild-type SAR405838 colon cancer sensitive detail...
Unknown unknown Enzastaurin colon cancer not applicable detail...
NRAS exon 2 Cetuximab colon cancer resistant detail...
NRAS exon 2 Panitumumab colon cancer resistant detail...
Unknown unknown Bevacizumab + FOLFIRI colon cancer not applicable detail...
Unknown unknown Torin 1 colon cancer not applicable detail...
BRAF V600E Gedatolisib colon cancer sensitive detail...
APC inact mut iCRT-3 colon cancer sensitive detail...
APC inact mut JW55 colon cancer sensitive detail...
APC inact mut iCRT-5 colon cancer sensitive detail...
APC inact mut iCRT-14 colon cancer sensitive detail...
APC inact mut G007-LK colon cancer sensitive detail...
Unknown unknown AR-42 colon cancer not applicable detail...
FGFR2 amp Ponatinib colon cancer sensitive detail...
FGFR2 amp Dovitinib colon cancer sensitive detail...
FGFR2 amp Cediranib colon cancer sensitive detail...
FGFR2 amp Nintedanib colon cancer sensitive detail...
FGFR2 amp Brivanib colon cancer no benefit detail...
FGFR2 wild-type Ponatinib colon cancer resistant detail...
Unknown unknown CFI-400936 colon cancer not applicable detail...
BRAF V600E Navitoclax + Vemurafenib colon cancer sensitive detail...
BRAF V600E Trametinib + Navitoclax colon cancer sensitive detail...
Unknown unknown AZD2811 colon cancer not applicable detail...
TP53 wild-type CPUY201112 colon cancer sensitive detail...
TP53 loss CPUY201112 colon cancer decreased response detail...
PTEN loss KU-55933 colon cancer sensitive detail...
Unknown unknown Ch282-5 colon cancer not applicable detail...
Unknown unknown Ch282-5 + Oxaliplatin colon cancer not applicable detail...
KRAS G13D Luminespib colon cancer sensitive detail...
ERBB2 L755S Trastuzumab colon cancer sensitive detail...
ERBB2 L866M Trastuzumab colon cancer sensitive detail...
ERBB2 S310F Trastuzumab colon cancer sensitive detail...
ERBB2 L755S Neratinib colon cancer sensitive detail...
ERBB2 V777L Neratinib colon cancer sensitive detail...
ERBB2 L866M Neratinib colon cancer sensitive detail...
ERBB2 S310F Neratinib colon cancer sensitive detail...
ERBB2 V842I Neratinib colon cancer sensitive detail...
ERBB2 V777L Trastuzumab colon cancer resistant detail...
ERBB2 V842I Trastuzumab colon cancer resistant detail...
NOTCH1 positive LY3039478 colon cancer sensitive detail...
APC wild-type CTNNB1 wild-type Vantictumab colon cancer predicted - sensitive detail...
KRAS mutant Ponatinib + Trametinib colon cancer decreased response detail...
Unknown unknown AZ628 + CPI-455 colon cancer sensitive detail...
Unknown unknown Irinotecan + Veliparib colon cancer not applicable detail...
BRAF V600E Cetuximab colon cancer resistant detail...
TP53 wild-type Trifluridine colon cancer sensitive detail...
BRAF V600E GDC0879 colon cancer sensitive detail...
BRAF N581Y GDC0879 colon cancer resistant detail...
KRAS mutant GDC0879 colon cancer resistant detail...
NRAS mutant GDC0879 colon cancer resistant detail...
BRAF wild-type KRAS G13D GDC0879 colon cancer resistant detail...
BRAF V600E PLX4720 colon cancer sensitive detail...
KRAS G13D APS-2-79 + Trametinib colon cancer sensitive detail...
Unknown unknown WANT3 colon cancer not applicable detail...
TP53 wild-type AMG 232 colon cancer sensitive detail...
TP53 wild-type AMG 232 + Radiotherapy colon cancer sensitive detail...
Unknown unknown AMG 900 colon cancer not applicable detail...
Unknown unknown Apatinib colon cancer not applicable detail...
Unknown unknown OMP-305B83 colon cancer not applicable detail...
KRAS G12D EZH2 pos DZNep + Selumetinib colon cancer no benefit detail...
KRAS G12D EZH2 pos DZNep + MK2206 colon cancer sensitive detail...
Unknown unknown HM-3 colon cancer not applicable detail...
Unknown unknown LF3 colon cancer not applicable detail...
FGFR2 amp AZD4547 colon cancer sensitive detail...
KRAS mutant Luminespib colon cancer predicted - sensitive detail...
KRAS G12V Luminespib colon cancer sensitive detail...
KRAS G12D Luminespib colon cancer sensitive detail...
Unknown unknown NU7441 + Radiotherapy colon cancer not applicable detail...
Unknown unknown Etoposide + NU7441 colon cancer not applicable detail...
Unknown unknown Doxorubicin + NU7441 colon cancer not applicable detail...
Unknown unknown Gemcitabine + SRA737 colon cancer not applicable detail...
BRAF V600E Panitumumab colon cancer resistant detail...
FGFR2 amp BGJ398 colon cancer sensitive detail...
BRAF mutant Selumetinib colon cancer predicted - sensitive detail...
KRAS mutant AZ-TAK1 colon cancer sensitive detail...
KRAS mutant AZ-TAK1 + Selumetinib colon cancer sensitive detail...
KRAS G12V AZ-TAK1 colon cancer sensitive detail...
KRAS mutant PF3644022 + PF-477736 colon cancer predicted - sensitive detail...
BRAF mutant PF3644022 + PF-477736 colon cancer predicted - sensitive detail...
Unknown unknown MPT0E028 colon cancer not applicable detail...
Unknown unknown Pracinostat colon cancer not applicable detail...
Unknown unknown Quisinostat colon cancer not applicable detail...
Unknown unknown Chiauranib colon cancer not applicable detail...
CTNNB1 over exp NVP-TNKS656 + Triciribine colon cancer predicted - sensitive detail...
KRAS A59T Panitumumab + FOLFIRI colon cancer sensitive detail...
Unknown unknown CVX-060 colon cancer not applicable detail...
Unknown unknown CVX-060 + Sunitinib colon cancer not applicable detail...
Unknown unknown CVX-060 + Sorafenib colon cancer not applicable detail...
Unknown unknown Bevacizumab + CVX-060 colon cancer not applicable detail...
Unknown unknown BGP-15 colon cancer not applicable detail...
Unknown unknown E7046 colon cancer not applicable detail...
Unknown unknown E7046 + Radiotherapy colon cancer not applicable detail...
KRAS mutant OPB-111077 colon cancer predicted - sensitive detail...
BRAF V600E TP53 Q192K Vemurafenib + Panitumumab colon cancer sensitive detail...
MLH1 loss KU60648 colon cancer sensitive detail...
MSH6 loss KU60648 colon cancer no benefit detail...
Unknown unknown CCT244747 + Irinotecan colon cancer not applicable detail...
BRAF V600E Cetuxmab + Sorafenib colon cancer predicted - sensitive detail...
KRAS exon 2 Cetuximab colon cancer resistant detail...
Unknown unknown NEO-102 colon cancer not applicable detail...
TP53 loss CHIR-124 + SN-38 colon cancer sensitive detail...
BRAF V600E Vemurafenib + Cetuximab + Irinotecan colon cancer sensitive detail...
BRAF V600E Vemurafenib + Panitumumab + Irinotecan colon cancer sensitive detail...
KRAS exon 3 Cetuximab colon cancer resistant detail...
KRAS exon 4 Cetuximab colon cancer resistant detail...
KRAS exon 2 Panitumumab colon cancer resistant detail...
KRAS exon 3 Panitumumab colon cancer resistant detail...
KRAS exon 4 Panitumumab colon cancer resistant detail...
NRAS exon 3 Cetuximab colon cancer resistant detail...
NRAS exon 4 Cetuximab colon cancer resistant detail...
NRAS exon 3 Panitumumab colon cancer resistant detail...
NRAS exon 4 Panitumumab colon cancer resistant detail...
FGFR2 amp FGFR2-COL14A1 Derazantinib colon cancer sensitive detail...
Unknown unknown SKLB-23bb colon cancer not applicable detail...
Unknown unknown IT-141 colon cancer not applicable detail...
Unknown unknown FN-1501 colon cancer not applicable detail...
ARID1A loss unspecified PD-L1 antibody colon cancer predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT01274624 Phase I FOLFIRI Bevacizumab + Reolysin Study of REOLYSIN; in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer Completed
NCT01730118 Phase I HER2 Vaccine Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing Recruiting
NCT01966289 Phase I Cyclophosphamide Guadecitabine GVAX colorectal cancer vaccine SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC) Active, not recruiting
NCT02014909 Phase I CDX-3379 CDX-3379 + Vemurafenib CDX-3379 + Trastuzumab Cetuximab + CDX-3379 CDX-3379 + Erlotinib A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors Completed
NCT02041481 Phase I MEK162 + FOLFOX MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer Completed
NCT02448173 Phase III A Multicenter Study of Active Specific Immunotherapy With OncoVax® in Patients With Stage II Colon Cancer Recruiting
NCT02508077 Phase II FOLFIRI Panitumumab FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Terminated
NCT02628535 Phase I MGD009 Safety Study of MGD009 in B7-H3-expressing Tumors Active, not recruiting
NCT02784795 Phase I Cisplatin + Gemcitabine + LY3039478 Carboplatin + Gemcitabine + LY3039478 LY3039478 + LY3023414 Abemaciclib + LY3039478 LY3039478 + Taladegib LY3039478 LY3023414 A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors Active, not recruiting
NCT02834052 Phase Ib/II Pembrolizumab + poly ICLC Pembrolizumab + Poly-ICLC in MRP Colon Cancer Recruiting
NCT02860780 Phase I Prexasertib + Ralimetinib A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer Completed
NCT02980029 Phase I TVB-2640 Pharmacodynamic Effects of Fatty Acid Synthase (FASN) Inhibition With TVB-2640 in Resectable Colon Cancer Recruiting
NCT03127098 Phase Ib/II ALT-803 + ETBX-011 QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer Active, not recruiting
NCT03199586 Phase I NP-G2-044 Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma) Recruiting
NCT03207867 Phase II PBF-509 + PDR001 A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma Recruiting
NCT03317119 Phase I Trametinib + trifluridine/tipiracil hydrochloride Trametinib and TAS-102 in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery Recruiting
NCT03631641 Phase II Nivolumab Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial Colectomy Recruiting
NCT03711058 Phase Ib/II Copanlisib + Nivolumab Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer Recruiting
NCT03801915 MVT-5873 Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers Not yet recruiting